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Abstract
Venezuelan equine encephalitis virus replicon particles (VRP) were engineered to express different
forms of SIV Gag to compare expression in vitro, formation of intra- and extracellular structures and
induction of humoral and cellular immunity in mice. The three forms examined were full-length
myristylated SIV Gag (Gagmyr+), full-length Gag lacking the myristylation signal (Gagmyr-), or a
truncated form of Gagmyr- comprising only the matrix and capsid domains (MA/CA). Comparison
of VRP-infected primary mouse embryo fibroblasts, mouse L929 cells and primate Vero cells showed
comparable expression levels for each protein, as well as extracellular virus-like particles (VRP-
Gagmyr+), and distinctive cytoplasmic aggregates (VRP-Gagmyr-) with each cell type. VPR were used
to immunize BALB/c mice, and immune responses were compared using an interferon (IFN)-γ
ELISPOT assay and a serum antibody ELISA. Although all three VRP generated similar levels of
IFN-γ-producing cells at 1 week post-boost, at 10 weeks post-boost the MA/CA-VRP-induced
response was maintained at a significantly higher level relative to that induced by Gagmyr+-VRP.
Antibody responses to MA/CA-VRP and Gagmyr+-VRP were not significantly different.
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Development of an effective vaccine against human immunodeficiency virus type 1 (HIV-1)
remains a critical need, especially in areas of high incidence where access to treatment is
limited. The effort to meet this need has involved new vaccine technologies, namely genetic
vaccines, which combine the safety of a subunit vaccine with the ability to present
endogenously produced proteins to the immune system, an advantage previously only
associated with live virus vaccines. Vaccine vectors based on purified DNA, live viruses, or
defective viruses differ in properties that may have a direct impact on their ability to induce
protective immunity to HIV-1, such as the cells that are targeted, the amount of immunogen
that is synthesized and persistence of the vector in the host (Amara and Robinson,
2002;Barouch et al., 2001;Schnell, 2001). Only head-to-head comparisons of vaccine vectors
can reveal their relative effectiveness, and some such comparisons have been reported in the
last few years (for examples, see Casimiro et al., 2003;Doria-Rose et al., 2003;Shiver et al.,
2002).
The molecular form of the immunogen is another important factor in the ultimate success of a
vaccine vector. The optimal configuration of a vaccine vector will require matching the specific
vector biology with the most immunogenic form of the vectored protein. For example, studies
of immunogen design have been performed in the context of DNA and canarypox vaccine
vectors expressing SIV or HIV-1 group-specific antigen (Gag) protein with widely varying
results. In the case of DNA, abrogation of Gag-directed budding increased the cellular immune
response in some cases (Bu et al., 2003;Young and Ross, 2006), but not in another (Qiu et al.,
2000), while the canarypox vector expressing budding-competent Gag was the most
immunogenic (Chen et al., 2005). This suggests that the distinct biology and specific design
of these genetic vaccines resulted in the determination of different optimal forms of Gag. It is
in this context that defective Venezuelan equine encephalitis virus replicon particle vectors
(VRP) expressing various forms of SIV Gag were compared both with respect to the properties
of the expressed proteins in cell culture and the strength and persistence of the cellular responses
induced in mice.
Several groups have demonstrated the importance of a cellular immune response in the natural
control of both HIV-1 and SIV replication (Borrow et al., 1994;Brander and Walker,
1999;Davis et al., 2002;Edwards et al., 2002;Koup et al., 1994;Letvin et al., 2006;Ogg et al.,
1998;Picker, 2000;Schmitz et al., 1999). For this reason, the Gag proteins of HIV-1 and SIV
are key targets in vaccine studies. They are expressed at a relatively high level by the virus,
are fairly conserved and carry a high density of CTL epitopes (Bertoletti et al., 1998;Johnson
et al., 1991;Johnson and Walker, 1994;Nixon, 1988;Riviere et al., 1989).
Two lines of evidence form the basis for the use of the full-length unmutated gag gene in the
majority of vaccine vectors. First, particulate antigens have been shown to be more
immunogenic than soluble proteins, possibly reflecting a structure-related adjuvant effect
(Michel et al., 1990;Paliard et al., 2000). Second, full-length myristylated Gag (Gagmyr+)
expressed in the absence of any other viral proteins is able to self-assemble into immature
virus-like particles (Delchambre et al., 1989;Gheysen et al., 1989;Wagner et al., 1992). It would
be expected that cytoplasmic Gagmyr+ would be processed for presentation on MHC class I
molecules and Gag-containing VLPs would be taken up by dendritic cells for processing
through both the MHC class I and class II pathways (Yewdell et al., 1999), thereby giving the
maximum immune response. However, the Gag protein can be produced in the cell in any of
several forms, which may influence the efficiency of antigen presentation. Bu, et al. (2003)
demonstrated that assembly and budding of the Gag immunogen is disrupted by mutating the
major homology region involved in multimerization or by inserting a protein destruction signal.
An alternative method for blocking Gag release is to mutate the glycine at codon 2 that is part
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of the signal for the co-translational modification of Gag with the fatty acid myristic acid. Gag
protein that lacks the myristic acid moiety (Gagmyr-) cannot target to the cell membrane and
is retained in the cytoplasm (Bryant and Ratner, 1990;Gottlinger et al., 1989;Qiu et al.,
2000;Rein et al., 1986). This cytoplasmic form of Gag is the immunogen that has been used
in the first clinical trial of a VRP vaccine, and preliminary, still blinded results have been
published (Chulay et al., 2006). Gagmyr+ and Gagmyr- represent two forms of the Gag protein
that could be processed through the MHC class I pathway to induce CD8+ T-cell responses.
Gag protein also has been expressed as a secreted unassembled protein by addition of the t-PA
signal sequence to its N-terminus (Qiu et al., 2000). An alternative form of Gag, comprised of
only the matrix and capsid (MA/CA) coding domain, has been shown previously to induce
both humoral and cellular immune responses, either delivered by viral vectors without the
myristylation signal (Caley et al., 1997;Davis et al., 2000), or by DNA vectors with the
myristylation signal (Bråve et al., 2005)
Gagmyr+ expressed in the context of the HIV genome assembles and forms extracellular,
enveloped particles in cultured primate cell lines. However, it has been reported that in mouse
cells that have been engineered to allow HIV entry and gene expression, HIV-1 Gagmyr+ fails
to localize to the plasma membrane or form virus particles (Chen et al., 2001;Mariani et al.,
2000). In a system using an HIV-1/murine leukemia virus pseudotype to infect murine cells
expressing human cyclin T1, assembly of infectious HIV-1 particles was demonstrated (Lund
el al., 2004). In work with virus vectors or DNA (Chen et al., 2005;Young and Ross, 2006)
and experiments presented here, Gagmyr+ expressed alone from a heterologous delivery system
can also overcome the block to assembly and efficiently produce extracellular Gag-containing
particles in murine cells.
In this study we utilized the VRP vector system (Davis et al., 2002;Pushko et al., 1997) to
produce phenotypically distinct forms of the SIVsmH-4i Gag protein in both primary and
transformed murine cell lines, as well as in a primate cell line. We found that three forms of
the Gag immunogen (Gagmyr+, Gagmyr- and MA/CA) were expressed to similar intracellular
levels in these cell lines. However, each form of Gag gave rise to a distinct molecular structure
that was consistently seen in all three cell types, including the budding of virus-like particles
directed by expressed Gagmyr+. The effect of these structural differences on immunogenicity
was tested in VRP-immunized BALB/c mice.
RESULTS
Expression of different forms of SIV Gag in VRP-infected monkey and murine cells
Figure 1 describes the different forms of the SIVsm H-4i Gag protein used in this study: i) full-
length myristylated Gag (Gagmyr+), ii) full-length non-myristylated Gag (Gagmyr-) and iii) a
non-myristylated fragment spanning the matrix and capsid domains (MA/CA). These were
expressed from individual VEE replicon vectors and packaged into VEE replicon particles
(VRP). The ablation of the myristylation site is predicted to prevent the association of Gag or
MA/CA with cellular membranes (Bryant and Ratner, 1990;Gottlinger et al., 1989;Rein et al.,
1986). The truncation of the polyprotein at the C-terminus of CA is expected to negatively
affect RNA binding and Gag-Gag interactions due to deletion of the interaction (I) domain in
NC (Bowzard et al., 1998;Dupraz and Spahr, 1992;Jowett, et al., 1992), as well as interactions
with cellular components involved in budding, ubiquitylation and endosomal sorting due to
deletion of the late (L) domain in p6 (reviewed in Morita and Sundquist, 2004).
The VRP were used to infect three different cell lines, Vero cells (a monkey kidney fibroblast
cell line), L929 cells (a mouse fibroblast cell line), and primary murine embryonic fibroblasts
(MEFs) from outbred CD-1 mouse embryos, to determine whether VRP-driven expression of
different forms of SIV Gag was altered in murine cells. Expression was assayed by SDS-
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polyacrylamide gel electrophoresis (SDS-PAGE) and Western blot (Fig. 2). Proteins with the
expected apparent molecular weights were detected in each lysate: myristylated or
nonmyristylated Gag (55kDa) or MA/CA (41kDa). The faster migrating bands in the
Gagmyr+ and Gagmyr- lanes likely represent products from a predicted internal initiation site
near the MA/CA boundary (Nicholson et al., 2006).
The analysis of intracellular protein production in monkey and mouse cells was extended using
the same assay, SDS-PAGE and Western blot, in a semi-quantitative comparison (Materials
and Methods). The results of two experiments (Table 1) show that VRP-infected Vero cells
and MEFs contain comparable amounts of each of the three forms of Gag.
The comparison of protein levels for a given form of Gag across cell types using the semi-
quantitative Western blot protocol accurately reflects the relative levels of protein production
in the primate and murine cells examined. However, when different forms of Gag are compared
for a single cell type, this protocol necessarily gives only an estimate because of possible
differences in accessibility of the capsid epitope to its cognate monoclonal antibody. For
example, it appears that Gagmyr+ is produced in greater amounts than Gagmyr- or MA/CA in
both cell types, even when, as in this analysis, the extracellular, budded Gagmyr+ is not included.
It may be that Gagmyr+, when bound to a nylon membrane, more efficiently displays the capsid
epitope, or is actually present in higher amounts due to greater stability in the cytoplasm of the
VRP-infected cell.
Each of the three forms of Gag protein expressed from VRP was evaluated for its ability to
direct budding of virus-like particles from monkey and mouse cell lines. As a first step, putative
viral particles in the culture supernatants were partially purified and concentrated by pelleting
through a 20% sucrose cushion. Proteins in the pellet were resuspended in PBS and examined
by SDS-PAGE and Western blot analysis. A protein of the correct apparent molecular weight
(55kDa) was detected in culture supernatants after expression of Gagmyr+ in all three cell lines,
but no supernatant viral proteins were seen after expression of Gagmyr- or MA/CA in any of
the three cell lines (Fig. 3; myristylation-minus results shown only for Vero cells).
In an alternative assay for particle production, a commercial ELISA (Zeptometrix) was used
to measure the amount of p55 Gag in high speed pellets of VRP-infected cell culture
supernatants collected 18 hours post-infection. In the absence of SIV protease expression, any
particles produced would be immature, containing the p55 precursor polyprotein. Using this
assay, it was determined that Vero cells produced 0.17 pg of p55 per cell and MEFs produced
0.75 pg of p55 per cell. More p55 also was observed in culture supernatants of Gagmyr+-VRP-
infected MEF cultures than Gagmyr+-VRP-infected Vero cells when assayed by Western blot
(Fig. 3). The reason for higher level p55-containing particle production from the MEFs is not
known, but taken together, these results demonstrate that VRP-Gagmyr+-infected primary
mouse cells are fully capable of producing extracellular Gag-containing particles.
Characterization of different forms of Gag protein by thin-section transmission electron
microscopy
To further evaluate the intracellular localization and morphology of each of the Gag proteins
expressed from the VRP, we examined both cell monolayers and pelleted supernatants from
each of the three cell lines by transmission electron microscopy (TEM). Particles corresponding
to the size of an immature SIV virion were detected by TEM of negatively-stained pelleted
culture supernatants from cells infected with VRP expressing myristy lated Gag but not
Gagmyr- or MA/CA (data not shown). Thin-section TEM of cell monolayers showed budding
particles at the surface of all three cell lines only when Gagmyr+ was expressed from the VRP
(Fig. 4A-C). Occasionally, Gagmyr+ particles could be observed budding into internal
membranes (data not shown). Expression of Gagmyr- unexpectedly produced stacked
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aggregates of Gag protein in the cytoplasm (Fig. 4D-F) that were not detected in any of the
cell lines infected with either Gagmyr+-VRP or MA/CA-VRP, or in mock infected cells.
Expression of the MA/CA form of Gag resulted in no discernable intracellular structures (MA/
CA and mock not shown).
The identity of the budding particles and the intracellular aggregates was confirmed by
immunogold labeling using an SIV Matrix-specific monoclonal antibody followed by TEM.
Both the budding particles and the intracellular aggregates were efficiently labeled with the
colloidal gold-conjugated anti-mouse IgG secondary antibody indicating that these two forms
did contain Gag protein (Fig. 5A-C). These TEM results confirmed the Western blot and p27
ELISA results showing Gag-containing particle production by Gagmyr+-VRP-infected monkey
and mouse cells, and revealed that high level expression from the VEE replicon vector of
Gagmyr-, a form of Gag that cannot associate normally with the plasma membrane, but retains
the I and L domains, leads to intracellular accumulation of distinctive aggregates. The
formation of such distinct Gag-containing structures in VRP-infected murine cells suggested
that changes in myristylation and aggregation might significantly affect the immunogenicity
of Gag in the VRP-immunized BALB/c mouse.
Identification of SIV Gag H-2d-restricted peptides
The ELISPOT assay for Gag-specific cellular immunity is a straightforward, quantitative
method for comparing the immunogenicity of two vaccines. To establish this assay for different
forms of Gag expressed by VRP in the BALB/c mouse, we tested a library of 125 peptides
representing the entire SIV Gag protein and identified the most reactive peptides in an IFN-γ
ELISPOT. Peptides spanning the Gag protein of SIVmac 239 (15-mers overlapping by 11)
were obtained from the NIH AIDS Repository and selectively mixed using an overlapping
checkerboard protocol. These mixtures were used in an ELISPOT assay to test their ability to
stimulate IFN-γ secretion by splenocytes taken from Gag-VRP vaccinated BALB/c mice
(H-2d), and three reactive peptides were identified (amino acid sequences in Materials and
Methods). Stimulation with any one of these peptides gave at least 70 spots per 1 × 106 cells
after subtraction of the average background seen with the irrelevant influenza HA peptide and
no peptide negative controls. All three reactive peptides map to the MA/CA region of Gag.
Results to be described were obtained with a pool of all three positive peptides.
To determine whether this pool of peptides contains determinants that are presented in the
context of class I or class II MHC antigens, or both, splenocytes were isolated from eight MA/
CA-VRP-immunized mice at 3 weeks post-boost, stimulated with the pool of three reactive
peptides and analyzed by intracellular cytokine staining (ICS) for IFN-γ. Flow cytometry was
used to measure intracellular IFN-γ staining of spleen cells that also had been stained for both
CD4 and CD8 (data not shown). Both CD4+ and CD8+ T cells expressed increased levels of
intracellular IFN-γ following stimulation with the peptide pool compared to cells incubated
with control peptides. Therefore, the pool of H-2d reactive peptides contains both class I and
class II determinants. This result is consistent with the induction of a balanced cellular immune
response by the VRP vectors, including both CD8+ T cells and CD4+ T helper cells, which
support T and B cell expansion.
Immunogenicity of the various forms of Gag in BALB/c mice
Having demonstrated that VRP-expressed forms of Gag give similar phenotypes in cultured
monkey cells and in primary mouse cells, and that in both of these cell types the different forms
of Gag are distinguished by their morphology and ability to form particles, groups of BALB/
c mice were vaccinated with each of the three VRP to test whether the phenotypes observed
in cell culture affect the immunogenicity of Gag.
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In three separate experiments, groups of BALB/c mice were each inoculated with a different
form of Gag-VRP at week 0 and boosted at week 4. At 5, 10 and 14 weeks (1, 6 and 10 weeks
post-boost) a subset of mice from each immunized group was euthanized, and splenocytes were
isolated and tested in an IFN-γ ELISPOT assay using a mixture of the three Gag-reactive
peptides (Fig. 6). In panels 6A-C the number of IFN-γ-producing cells (spots) per 1 × 106
splenocytes for individual mice harvested at each time point are represented as the percent of
the median number of spots detected at week 5 for each VRP group. This representation
illustrates the relative decrease in the antigen-specific cellular response at later times post-boost
for the three VRP groups. A comparison of the difference between the 100% level (equal to
the median at week 5) and the median percent at weeks 10 and 14 for each VRP group (shown
by the bars) shows that a higher number of Gag-specific IFN-γ-producing cells are maintained
in the MACA-VRP group than in the Gagmyr+-VRP group at both later time points. The
decrease in median spot numbers during the time course from the acute phase (5 weeks, set at
100%) to the memory phase (14 weeks) for each VRP group in the individual experiments is
shown in Figure 6D-F.
Statistical comparisons of the number of IFN-γ-producing cells per 1 × 106 splenocytes were
made among the three VRP groups at each time point, and between each VRP group at each
time point, combining values for all three experiments (Table 2). This analysis showed a
significant difference across all groups at week 10 (median values of 211, 319 and 305, p =
0.03) and at week 14 (median values of 163, 182 and 242, p = 0.006). When the three
experiments were examined in pairwise comparisons, we observed a highly significant
difference at week 14 between Gagmyr+ and MA/CA both in terms of spots per 1 × 106
splenocytes (median values 163 and 242, p = 0.0002; Table 2) and percent of median spots per
1 × 106 cells at week 5 (median values = 0.377 and 0.670, p < 0.0001; Fig 6C). Taken together,
these results show that immunizations with VRP expressing different forms of Gag give acute
cellular immune responses in BALB/c mice that are statistically equivalent, but that at later
times the response to MA/CA-VRP is maintained at a significantly higher level than that to
Gagmyr+-VRP, with a 50% greater median number of IFN-γ-secreting cells at week 14 in the
combined experiments. Although the cellular responses to all types of Gag-VRP decreased
between 5 weeks and 14 weeks, as would be expected in a comparison of IFN-γ-secreting cells
in the acute and memory phases of the response, in each case the decrease was less when MA/
CA was the immunogen.
The humoral immune responses induced by Gagmyr+-VRP, Gagmyr--VRP and MA/CA-VRP
vaccination were compared using an ELISA assay with purified MA/CA protein as the antigen
(Davis et al., 2000). Median titers at 10 weeks post-boost in the three separate mouse
immunization experiments described above were 10,000, 20,000, and 7,500 for Gagmyr+,
20,000, 60,000, and 10,000 for Gagmyr- and 10,000, 20,000 and 5,000 for MA/CA, respectively.
Two-group comparisons showed that Gagmyr- induced significantly more binding antibody
than Gagmyr+ in two of three experiments (p = 0.002, 0.02, and 0.46), and in one of three
experiments induced more than MA/CA (p = 0.001, 0.10, and 0.12). ELISA titers induced by
Gagmyr+ and MA/CA were not significantly different (p = 0.99, 0.61, and 0.78).
DISCUSSION
The goal of this study was to determine the expression, morphologic and immunogenic
phenotypes of three alternative forms of SIVsm H-4i Gag using the VRP vector in the mouse
model. The result would be considered when choosing immunogens for ongoing primate
studies in support of HIV-1 vaccine development for humans. These experiments also represent
an example of an empirical head-to-head test of different forms of the same immunogen to
determine the form that takes best advantage of a specific vector biology.
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Two developments paved the way for the use of VRP in the BALB/c mouse in this study. First,
using SIV Gag-VRP we demonstrated that three distinct forms of SIVsm H-4i Gag show similar
in vitro phenotypes in both a primate cell line and primary mouse fibroblasts. Second, reactive
SIV MA/CA peptides were identified in an IFN-γ ELISPOT assay for BALB/c mice. These
combined results indicated that Gag-VRP vaccination of the BALB/c mouse would be a useful
model in which to compare different forms of SIV Gag for their ability to induce a cellular
immune response.
Although the very distinct molecular structures found in cultured monkey and murine cells
suggested that the three forms of Gag might differ dramatically in immunogenicity, our results
revealed no significant difference in the humoral responses or in the acute phase of the cellular
response. However, in IFN-γ ELISPOT assays, the average number of Gag-reactive
splenocytes was maintained at a 50% higher level in the memory phase when MA/CA was the
immunogen.
The incremental improvement in maintenance of antigen-specific T cells, as opposed to any
dramatic increase in the initial cellular response, may reflect the identity of the VRP-infected
cell. Wild-type VEE and VRP packaged with wild-type glycoproteins are found very soon after
infection in dendritic cells in the draining lymph node with the properties of antigen-presenting
cells. However, mutations in the glycoproteins, such as those used in this study, direct the VRP
to different cells in the draining lymph node (MacDonald and Johnston, 2000; West and
Johnston, unpublished results), cells which may be involved in cross-presentation rather than
direct presentation of antigens. In the context of a cross-presenting cell, the different molecular
structures of Gag immunogen tested here may have only a small, but nonetheless significant,
impact on the immune response induced by VRP vaccination. The further characterization of
VRP target cells in the lymph node is currently underway.
The nature of the cellular target was addressed in a previous study of intramuscular DNA
vaccination, in which the expressed Gagmyr- immunogen gave lower level CTL responses than
expression of either particle-forming Gagmyr+ or secreted, non-particle forming Sc-Gag (Qiu,
et al., 2000). One interpretation of this result is that transfer of protein from transduced muscle
cells to migratory dendritic cells (cross-presentation) is more efficient with the secreted forms
of Gag.
At the outset of this study, we could not assume that different forms of Gag would behave in
the mouse model the same way they behave in the more relevant primate background. There
are numerous steps in the HIV-1 replication cycle that appear to be blocked in mouse cells
(Atchison et al., 1996;Feng et al., 1996;Landau et al., 1988). It has been observed that assembly
at the plasma membrane of murine cells occurs at very inefficient levels (Mariani et al.,
2000). Using the VRP system, we were able to induce particle budding in a primate cell line
(Vero) and in both transformed (L929) and primary (MEF) murine cells. It is likely that the
overexpression of Gag from the strong 26S promoter of the VRP overcame the assembly block
in the murine cells and allowed Gagmyr+ to assemble and bud (Hatziioannou et al., 2005).
Infection of a murine myocyte cell line, C2C12, with a canarypox vector expressing HIV Gag,
protease and Env also showed budding of virus-like particles (Chen et al., 2005). It may be
that expression levels in this vector system also were sufficiently high to overcome the block
to assembly.
Unexpectedly, expression of Gagmyr- by the VRP vector resulted in accumulation in the
cytoplasm of distinctive Gag-containing aggregates that often had the appearance of concentric
arcs associated with small electron dense particles. It is possible that aggregation results from
high level expression of full-length mutated Gag that cannot associate with the plasma
membrane. Although purely speculative, it may be that the specific morphology shown by the
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Gagmyr- aggregates represents an early stage in the development of an aggresome whose
maturation has been aborted due to VRP effects on cellular biosynthesis (Kopito, 2000).
The canarypox vector expressing nonmyristylated Gag did not produce an intracellular
aggregated form, perhaps because the intracellular concentration was not high enough, or
because protease was also expressed from that vector (Chen et al., 2005). However, an
aggregate with similar morphology was detected in insect cells infected with a baculovirus
vector expressing SIV Gagmyr+-Pol (Yamshchikov et al., 1995). In this case, the level of
Gagmyr+ expression from the baculovirus vector may have saturated the limited sites for
budding and raised the cytoplasmic concentration of Gag over the threshold for aggregation.
In the context of the VRP vector, our results show that delivery of MA/CA maintains a
significantly greater number of antigen-specific IFN-γ-secreting splenocytes during the
memory phase compared to Gagmyr+, suggesting that among the forms of Gag tested, MA/CA
is the immunogen of choice for this vaccine vector. The modest improvement in the longevity
of the response induced by this altered form of Gag may or may not translate into other vaccine
vector systems. However, it is likely that the most effective HIV vaccine will combine several
such incremental improvements, and with that in mind, the MA/CA form of Gag should be
considered when testing vaccine vectors for efficacy against HIV.
MATERIALS AND METHODS
Cells and plasmids
Vero and L929 cells were obtained from the American Type Culture Collection and were
maintained as recommended. BHK cells were maintained and prepared for electroporation as
described previously (Davis et al, 2000;Liljeström and Garoff, 1991).
The SIVsm H-4i full-length clone (Hirsch et al., 1989) was used as the template for PCR to
generate the gag genes that were inserted into the pVR21 vector (Balasuriya et al, 2000).
Primers were designed to amplify from the 3’ end of the nsp4 gene of VEE through the 26S
promoter and the 5’ leader of the 26S mRNA. Overlapping PCR was used to join this VEE
vector-derived fragment upstream of the following gag gene segments: (i) the full-length
gag gene encoding the intact myristylation signal (encoding Gagmyr+), (ii) the full-length
gag gene with a change in codon 2 from Gly to Ala to ablate the myristylation signal (encoding
Gagmyr-), and (iii) the matrix-capsid region of gag also containing the change in codon 2
(encoding MA/CA). The overlapping PCR products spanned from either the AvrII site (nt 5952
from the VEE 5’ end) or the SwaI site (nt 6962) in nsP4, through the 26S mRNA promoter and
the SIV gene to a unique PmeI site added at the 3’ end of the SIV sequence. This PCR product
was cloned into the PCR-Blunt vector (Invitrogen) and validated by sequencing. Flanking
upstream AvrII or SwaI sites and the downstream PmeI site were then used to subclone the
26S transcription units with the SIV genes into the p VR21 vector. For the first two mouse
immunization experiments, a non-myristylated MA/CA-expressing p VR2 vector was used
(Davis et al., 2000), which differs from the MA/CA-expressing p VR21 vector described above
only in that a different cloning strategy for p VR2 necessarily omitted the downstream 14 nts
of the 30 nt-long 26S mRNA 5’ leader. The MA/CA-expressing p VR21 vector containing the
full leader sequence was compared to the p VR2 vector with respect to level of MA/CA
expression in MEFs and induction of cellular immunity in the third mouse immunization
experiment. The two MA/CA vectors gave comparable levels of expression in vitro and
statistically equivalent numbers of interferon (IFN)-γ-secreting cells in the ELISPOT assay at
both 1 and 10 weeks post-boost. Therefore, the results for both of these vectors were combined
for statistical comparison to Gagmyr- and Gagmyr+.
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Each of the VEE Gag expression vectors was used in an in vitro transcription reaction
(mMessage mMachine, Ambion, Inc.) to generate VEE replicon RNA. Capsid helper RNA
and V3014 glycoprotein helper RNA (encoding independently attenuating mutations in the E1
and E2 glycoproteins; Grieder et al., 1995) were transcribed in vitro from separate plasmids
for co-electroporation with the gag replicon RNA to produce VEE replicon particles (VRP).
VRP were partially purified, and the infectious units(IU)/ml were determined for each
preparation on BHK cell monolayers as described previously (Davis et al, 2000;Pushko et al,
1997).
Preparation of primary murine embryo fibroblasts (MEFs)
Pregnant CD-1 female mice (E13) were obtained from Charles River Labs. Embryos were
harvested at 15-16 days gestation, rinsed in PBS, then transferred to complete medium
(Dulbecco’s minimal essential medium with 10% FBS, 2mM L-glutamine, 100U/ml penicillin,
0.1mg/ml streptomycin and 10mM HEPES). Tissue was minced with a sterile razor then
homogenized by passing through a 16G needle several times. The homogenate was incubated
with trypsin at 37°C for a total of 90 minutes, during which time additional trypsin was added
to the cells at 30 minute intervals. Cells were incubated on ice for 10 minutes to allow large
aggregates to settle out and then the supernatant was centrifuged for 10 min at 1000× g at 4°
C. The resulting pellet was resuspended in complete medium, and the cells were plated, allowed
to grow at 37°C, 5% CO2 and passed twice to select for adherent fibroblasts before trypsinizing
and freezing in DMSO-containing freezing medium. Prior to use, cells were thawed, plated
and passed once.
Western blot analysis of cultured cell lysate and supernatants
Monolayers of each cell type were prepared and grown to ∼80% confluence. Parallel cultures
were infected with each VRP at a multiplicity of infection (MOI) of 10 (10 IU per cell) and
incubated at 37°C for 16-18 hrs prior to harvest. Cell supernatants were collected and
centrifuged at 18,000× g for 5 min to remove cell debris and nuclei. Supernatant Gag particles
were then partially purified and concentrated by pelleting through a 20% sucrose cushion for
16-18hrs at 13,000× g at 4°C. The cell monolayer was rinsed with PBS and lysed in a buffer
containing 0.05M Tris (pH 7.5), 0.1M NaCl, 0.1% EDTA, 0.2% NP40 and a protease inhibitor
cocktail (Complete, Roche Applied Science). The cell lysate was collected and centrifuged at
18,000× g for 5 min to remove cell membrane fragments and nuclei. Aliquots of the pelleted
culture supernatants and the clarified cell lysates were dissociated in 1% sodium dodecyl sulfate
(SDS) and 2.75mM β-mercaptoethanol and their constituent proteins were resolved on a
NuPAGE 4-12% Bis-Tris polyacrylamide gel (Invitrogen) and transferred to PVDF membrane
(Amersham). After blocking overnight in 5% Amersham membrane blocking agent in Tris-
buffered saline solution with Tween 20 [TBST: 0.1M Tris-HCl, pH 7.5, 0.9% (w/v) NaCl,
0.1% (v/v) Tween 20], the membrane was incubated with SIV capsid-specific monoclonal
antibody KK64 (NIH AIDS Repository Cat.#2321, Kent et al., 1991) at a dilution of 1:1000
in blocking solution. As the epitope for this monoclonal antibody is in SIV capsid, it would
react with all forms of Gag protein used in this study. The membrane was washed thoroughly
and incubated with an HRP-conjugated horse anti-mouse IgG secondary antibody (Promega)
at a 1:1000 dilution in TBST. Antibody-binding bands were detected using enhanced
chemiluminescence (ECL-Amersham) and Kodak Biomax film.
A semi-quantitative Western blot was performed as follows. Any cells that had been released
into the culture supernatant during the 18 hours of infection were collected by centrifugation,
lysed and added to the lysate of attached cells. This was necessary because of the greater number
of floating cells in the Gagmyr+ cultures than in the Gagmyr- and MA/CA cultures. Also, a series
of preliminary Western blots was performed to determine the amount of cell lysate and anti-
capsid (CA) monoclonal antibody KK64 needed to give an excess of antibody over antigen,
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thereby detecting total antigen in each lysate. For the final Western blot, an equal number of
lysed cell equivalents was applied to the gel for each cell line infected with each VRP, and an
amount of antibody known to be in excess of each antigen was used for detection. Appropriate
bands in the final blots were quantified using Image J software.
Transmission electron microscopy and immunogold labeling
Each of the three cell lines (Vero, L929 and MEF) was infected with each of the VRP at an
MOI of 10. Cell supernatants were removed, and the cell monolayers were fixed with 3%
glutaraldehyde in 0.15M sodium phosphate buffer and post-fixed with potassium ferrocyanide-
reduced osmium tetroxide. Cells were embedded in situ in Polybed 812 epoxy resin and cut
into ultrathin sections of 70 nm. Sections were post-stained in uranyl acetate and lead citrate,
then photographed using a LEO EM-910 transmission electron microscope (LEO Electron
Microscopy Inc. Thornwood, NY) at 80KV. All sections were cut parallel to the substrate.
For immunogold labeling of the Gag particles, cells were fixed in 2% paraformaldehyde, 0.5%
glutaraldehyde. Cells were embedded in L.R. White resin, sectioned parallel to the substrate
at 80 nm, labeled using a 1:100 dilution of a monoclonal antibody to SIV Matrix (KK59 - NIH
AIDS Repository Cat.# 2320, Kent et al., 1991), followed by a 1:50 dilution of a goat anti-
mouse IgG secondary antibody conjugated to a 5 nm colloidal gold particle (Polysciences, Inc.,
Warrington, PA Cat.# 22730). KK59 monoclonal antibody, like KK64 described above,
reacted with all forms of Gag used in this study and gave better binding than KK64 under the
fixation conditions required for electron microscopy. Immunogold labeling was followed by
staining in uranyl acetate and lead citrate and sections were photographed as above.
Quantitation of extracellular particle production by p27 ELISA
Pellets obtained by high speed centrifugation of culture supernatants were resuspended in a
total volume of 200 μl and analyzed using a Retro-tek SIV p27 antigen ELISA kit (Zeptometrix)
according to the manufacturer’s recommendations. Determination of protein amount was made
by comparison to an antigen standard curve using a p27 sample provided by the manufacturer.
Duplicate values were averaged, and an average background value for mock-infected cells was
subtracted. Final values (pg/ml) were multiplied by total volume and divided by the number
of cells from which the supernatant was collected to derive pg of p27 per cell.
VRP vaccination of BALB/c mice
Five-week-old BALB/c mice were obtained from Charles River Labs and housed in accordance
with NIH and institutional guidelines. Eight mice per group per time point were each vaccinated
with VRP expressing either Gagmyr+, Gagmyr- or MA/CA at a total dose of 1×106 IU in 20 μl
split equally between the rear footpads. Vaccinations were given at 0 and 4 weeks. Serum was
collected one day prior to the priming dose, one day prior to the boost, and during the harvesting
of the spleen at 1, 6 or 10 weeks post-boost.
Identification of SIV Gag H-2d-restricted peptides
The SIVmac239 Gag peptide library (AIDS Research and Reference Reagent Program, Cat.#
6204) consists of 125 15-mer peptides that overlap by 11 amino acids. Peptides were pooled
and arranged in an overlapping checkerboard as previously described (Kern et al., 1999; Guido
Ferrari, personal communication). Each pool consisted of 11 consecutive peptides and 12
overlapping peptides. The checkerboard was constructed such that one peptide was present in
each of two otherwise independent pools. Using the intersection of these pools, an individual
reactive peptide was easily identified. The peptide pools were used in an IFN-γ ELISPOT assay
(see below) at a final concentration of 2 μg/ml to stimulate splenocytes isolated from
immunized BALB/c mice. The mice were given two doses of 1 × 106 IU of Gagmyr+-VRP at
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0 and 4 weeks. An IFN-γ ELISPOT assay was performed 3 weeks post-boost. The initial
ELISPOT assay identified several candidate pools. The individual peptides that comprised
these pools were then tested in a second IFNγ ELISPOT assay, thereby identifying three
reactive peptides: KQIVQRHL VVETETGTT (Cat.# 5236), NIYRRWIQLGLQKCV
(Cat.#5276) and YVDRFYKSLRAEQTD (Cat.#5285). Stimulation of splenocytes from mice
immunized with VRP-Gagmyr+ with a pool of these three peptides gave 104, 158 or 74 spots
per 106 cells, respectively, compared to 14 spots per 106 cells with a pool of three negative
peptides (Cat.#’s 5211, 5233 and 5255).
Assay of cellular immune response by IFN-γ ELISPOT
Multiscreen 96-well filtration plates (Millipore MHABS4510) were incubated overnight at 4°
C with 100 μl per well of a 5μg/ml solution of antibody to mouse IFN-γ (AN18 Mabtech) in
sodium bicarbonate buffer (pH 9.6), washed with PBS and blocked with AIM V (Invitrogen),
5% FBS medium. After blocking, plates were washed again prior to adding peptides at a final
concentration of 2 μg/ml in a volume of 50 μl.
Groups of vaccinated mice were euthanized according to institutional guidelines at week 1, 6
or 10 post-boost. Spleens were removed and disrupted with a syringe plunger. The single cell
suspensions were then washed twice in a 1:10 dilution in PBS of Alsever’s solution (8g
dextrose, 5.5g citric acid, 4.2g sodium chloride in a final volume of 1 L, PBS/A). The red blood
cells were lysed by adding 1 ml of sterile water, immediately followed by 9 ml of PBS/A. Cells
were washed twice again, then resuspended in RPMI medium. Splenocytes were overlaid onto
a Lympholyte M cushion (Cedarlane) and centrifuged for 30 min at 2500 rpm and 20°C. The
buffy coat was removed, resuspended in PBS/A and washed twice. After the last wash, cells
were resuspended in AIM V medium without added serum, counted and adjusted to 1 × 107
cells/ml and 50 μl were plated into wells of anti-IFN-γ antibody coated 96 well plates containing
either 50 μl of peptide(s) to be tested, an irrelevant control influenza virus hemagglutinin (HA)
peptide (IYSTVASSL), or a no peptide control. Three 15-mer SIV Gag peptides identified
from the mapping IFN-γ ELISPOT assays, Cat.#5236, Cat.#5276 and Cat.#5285, were used
individually and as a pool of 3 in this assay. The plates were incubated undisturbed for 20-24
hours at 37°C and 5% CO2. Plates were washed with chilled distilled water, incubated on ice
for 10 minutes, washed 10 times with wash buffer (PBS with 0.01% Tween-20) and then
incubated with 100 μl per well of 1μg/ml of biotinylated antibody to mouse IFN-γ (R4-64A2,
Mabtech) in PBS containing 0.01% Tween-20, 1% bovine serum albumin (BSA) for 16-18
hours at 4°C. After the incubation, plates were washed ten times with wash buffer. Strepavidin-
alkaline phosphatase (Mabtech) was diluted 1:1000 in PBS/0.01% Tween-20/1% BSA,
100μl was added to each well and plates were incubated for 1-2 hours at 25°C. Plates were
washed 10 times and spots were developed with 100 μl of BCIP/NBT substrate (Promega)
prepared according to the manufacturer’s instructions. Spots were counted using an automated
plate reader with Immuno Spot software (Cellular Technology Ltd.).
Three non-reactive SIV Gag peptides were used as negative controls in addition to the irrelevant
Kd HA peptide (IYSTVASSL) and no peptide sample. Averaged negative HA and no peptide
control values for each spleen were subtracted from the individual samples. Concanavalin A
at a concentration of 5 μg/ml was included in two wells of each splenocyte preparation as a
positive control for the presence of viable T cells.
ELISA for anti-MA/CA antibody
Antisera were tested for antibody against MA/CA as described previously (Davis et al.,
2000) except that six-His-tagged MA/CA protein was made in Escherichia coli strain
BL21DE3 using the pET24a expression plasmid. Horseradish peroxidase-linked anti-mouse
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IgG (Sigma) was used as the secondary antibody. Titers represent the highest serum dilution
that gave an optical density at 450 nm of ≥ 0.2.
Statistical analysis of ELISPOT results
Nonparametric one-way analysis of variance (the Kruskal-Wallis test using Van der Waerden
normal scores) was used to evaluate possible differences in ELISPOT and ELISA responses
across the Gagmyr+, Gagmyr- and MA/CA groups. The Wilcoxon rank-sum test (using Van der
Waerden normal scores) was used for the two-group comparisons of Gagmyr+ to Gagmyr-,
Gagmyr+ to MA/CA, and Gagmyr- to MA/CA. Monte Carlo estimates of exact p-values were
used. The Bonferonni method was used to adjust p-values to account for multiple comparisons.
All of these statistical analyses were performed using SAS statistical software, Version 9.1,
SAS Institute Inc., Cary, NC. The Mann-Whitney Test was used to compare values for the
Percent of Median Spots per 1×106 Cells at Week 5 for the Gagmyr+-VRP and MA/CA-VRP
groups at week 14 (Instat program, GraphPad Software).
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Diagram of three forms of the SIV Gag protein expressed from the VEE replicon expression
vector. The approximate locations of the M, membrane targeting domain, MHR, major
homology region, I, interaction domain, L, late domains and x, mutant myristy lation site are
shown.
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Cell-associated Gag protein in VRP-infected cultured cells. Vero cells (lanes 1-4), L929 cells
(lanes 5-8) and MEFs (lanes 9-12) were infected at a multiplicity of infection of 10 with VRP
expressing either MA/CA (lanes 2,6,10), Gagmyr- (lanes 3,7,11) or Gagmyr+ (lanes 4,8,12) or
mock infected (lanes 1,5,9). At 18 hours post-infection monolayers were lysed with NP-40 and
the lysate analyzed by SDS-PAGE on a 4-12% gradient polyacrylamide gel followed by
Western blot with an anti-Capsid monoclonal antibody.
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Extracellular Gag protein in cultures of VRP-infected cells. Vero cells (lanes 1-4), L929 cells
(lane 5) and MEFs (lane 6) were infected as described for Figure 2 with VRP expressing either:
MA/CA (lane 2), Gagmyr- (lane 3) and Gagmyr+ (lanes 4-6). Cell supernatants were collected
at 18 hours post-infection, layered over a 20% sucrose cushion and centrifuged. Pellets were
resuspended in PBS, dissociated with SDS and β-mercaptoethanol, and analyzed by SDS-
PAGE and Western blot as described for Figure 1.
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Thin section electron microscopy of VRP-infected cultured cells. Vero cells (A,D), L929 cells
(B,E) or MEFs (C,F) were infected as for Figure 2 with either Gagmyr+-VRP (A-C) or
Gagmyr--VRP (D-F). At 18 hours post-infection monolayers were fixed, embedded, sectioned
and stained for TEM as described in Materials and Methods. Representative fields are shown
for each culture at the same magnification.
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Immunogold labeling followed by thin section electron microscopy of VRP-infected vero cells.
Cells were infected as for Figure 2 and fixed at 18 hours post-infection. Monolayers were
sectioned, treated with anti-Matrix monoclonal antibody followed by colloidal gold-
conjugated anti-mouse IgG antibody then stained with uranyl acetate and lead citrate.
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ELISPOT assay of splenocytes from Gag-VRP immunized BALB/c mice. Mice were
immunized with Gagmyr+-, Gagmyr-- or MA/CA-VRP at weeks 0 and 4. Splenocytes were
harvested from groups of mice at either week 5, 10 or 14 and stimulated with a pool of Gag-
reactive peptides in an IFN-γ ELISPOT assay (Materials and Methods). A: IFN-γ-secreting
cells (spots) per 1 × 106 cells in individual spleens for the three independent experiments
combined plotted as a percent of the median number of spots detected at 5 weeks (1 week post-
boost). N = 24 for Gagmyr+, N = 24 for Gagmyr-, N = 34 for MA/CA. B: Spots per 1 × 106 cells
at 10 weeks (6 weeks post-boost) plotted as a percent of the median number of spots detected
at 5 weeks. Bars represent median percents for each group at 10 weeks. N = 16 for all groups.
Experiment three did not include a 10 week time point. C: Spots per 1 × 106 cells at 14 weeks
(10 weeks post-boost) plotted as a percent of the median number of spots detected at 5 weeks.
Bars represent median percents for each group at 14 weeks. N = 24 for Gagmyr+, N = 24 for
Gagmyr-, N = 31 for MA/CA. D.-F.: Median spots per 1 × 106 cells for each of three independent
experiments represented as a percent of the median spots per 1 × 106 cells at week 5. Insets
show the median spots per 1 × 106 cells at 5 weeks for each group in each experiment. Solid
inverted triangles, MA/CA group; open circles, Gagmyr- group; solid circles, Gagmyr+ group.
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